Efficacy and safety of valsartan in reducing blood pressure and albuminuria in Chinese patients with essential hypertension: a multicenter prospective open-label observational study

References

• Cerasola G, Cottone S, Mule G. The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. J Hypertens 2010;28:2357-69
   PubMed Web of Science ®Google Scholar
• Blouza S, Dakhli S, Abid H, et al. Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol 2010;23:415-24
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a BP-independent effect. Circulation 2002;106:672-8
   PubMed Web of Science ®Google Scholar
• Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25:1921-6
   PubMed Web of Science ®Google Scholar
• Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-9
   PubMed Web of Science ®Google Scholar
• Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006;47:751-60
   PubMed Web of Science ®Google Scholar
• Sun NL, Zhu JR, Zhao Y, et al. Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension. Current medical research and opinion 2008;24:2863-71
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Palmer BF. Management of hypertension in patients with chronic kidney disease and diabetes mellitus. Am J Med 2008;121:S16-22
   PubMed Web of Science ®Google Scholar
• de Boer IH, Ioannou GN, Kestenbaum B, et al. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007;50:69-77
   PubMed Web of Science ®Google Scholar
• Halbesma N, Kuiken DS, Brantsma AH, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006;17:2582-90
   PubMed Web of Science ®Google Scholar
• Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep 2010;12:364-8
   PubMed Web of Science ®Google Scholar
• Brouwers FP, Asselbergs FW, Hillege HL, et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 2011;161:1171-8
   PubMed Web of Science ®Google Scholar
• Chen YY, Li YY, Lu YH, et al. Albuminuria independently predicts cardiovascular and all-cause mortality in a middle-aged and elderly Chinese population. Scand J Clin Lab Invest 2012;72:281-6
   PubMed Web of Science ®Google Scholar
• Sheng CS, Hu BC, Fan WX, et al. Microalbuminuria in relation to the metabolic syndrome and its components in a Chinese population. Diabetol Metab Syndr 2011;3:6
   PubMed Web of Science ®Google Scholar
• de la Sierra A, Bragulat E, Sierra C, et al. Microalbuminuria in essential hypertension: clinical and biochemical profile. Br J Biomed Sci 2000;57:287-91
   PubMed Web of Science ®Google Scholar
• Mykkanen L, Zaccaro DJ, Wagenknecht LE, et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998;47:793-800
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
   PubMed Web of Science ®Google Scholar
• Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17
   PubMed Web of Science ®Google Scholar
• Uzu T, Sawaguchi M, Maegawa H, et al. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007;30:1581-3
   PubMed Web of Science ®Google Scholar
• Uzu T, Sawaguchi M, Maegawa H, et al. Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART). Hypertens Res 2008;31:1171-6
   PubMed Web of Science ®Google Scholar
• Csibi A, Communi D, Muller N, et al. Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms. PloS one 2010;5:e10070
   PubMed Web of Science ®Google Scholar
• van der Zijl NJ, Moors CC, Goossens GH, et al. Valsartan improves beta-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care 2011;34:845-51
   PubMed Web of Science ®Google Scholar
• Lee JM, Kim JH, Son HS, et al. Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension. J Int Med Res 2010;38:234-41
   PubMed Web of Science ®Google Scholar
• Pscherer S, Heemann U, Frank H. Effect of renin-angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance. Diabetes Care 2010;33:914-19
   PubMed Web of Science ®Google Scholar